CA Patent

CA2763894A1 — Use of rifaximin to maintain remission of hepatic encephalopathy

Assigned to Salix Pharmaceuticals Inc · Expires 2011-01-13 · 15y expired

What this patent protects

Treatment of hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic enc…

USPTO Abstract

Treatment of hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The further provided are methods for treating these subjects.

Drugs covered by this patent

Patent Metadata

Patent number
CA2763894A1
Jurisdiction
CA
Classification
—
Expires
2011-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.